Absolute light intolerance: Erythropoietic protoporphyria (EPP)

Erythropoietic protoporphyria (EPP) is a rare and severe UV/light related skin disorder. The Australian outdoor lifestyle has ingrained in us a distinct awareness and understanding of the dangers of sunlight and UV exposure. This unique insight makes knowledge of photodermatoses (UV/Light related skin disorders) all the more profound. Erythropoietic protoporphyria (EPP) is a rare genetic […]

 
“Separate yourself from the pain”

Adrian was diagnosed with the genetic disease Erythropoietic Protoporphyria (EPP) when he was 5. Exposure to light causes him excruciating pain. EPP is characterised by the accumulation of toxic compounds in the body of patients. Exposing an EPP patient’s skin to light, particularly blue light, causes excruciating pain: intense burning, stinging heat. Adrian describes EPP […]

 
Clinuvel, improving quality of life

Afamelanotide holds promise as a preventative pharmaceutical treatment, improving quality of life for patients with advanced stage bile duct cancer, who are eligible to undergo Photodynamic Therapy (PDT). CLINUVEL is committed to caring for patients who do not receive medical attention for light and UV related diseases. We believe strongly in prevention and we are […]

 
“Where no one has gone before”

CLINUVEL Non-Executive Director Jack Wood discusses commercialization. CLINUVEL is developing a breakthrough photoprotective drug, Scenesse (afamelanotide), to be administered every 60 days. Scenesse is selective in its pharmacologic action by activating skin’s own pigment, melanin. It is due to melanin that a physical barrier between skin and light of all wavelengths -particularly UV- is provided. […]

 
“the golden age?”

CLINUVEL Non-Executive Chair Brenda Shanahan and Non-Executive Director Roger Aston discuss the progress of CLINUVEL’s clinical program with Scenesse (Afamelanotide) Administered by physicians as a controlled-release resorbable implant, Scenesse is a preventative drug activating melanin – pigmentation – in the skin. Melanin provides a biological barrier, protecting skin from UV and visible light. Medically, this […]

 
Clinuvel’s regulatory strategy

CLINUVEL’s CSO, Dr Hank Agersborg, on the final year of drug filing CLINUVEL’s ASX announcement on the SU results can be found here. Read the CEO’s Technical note on the Phase II results here. This audio file is available for download in mp3 format. Right click here and select “Save target as” to save this file to your computer.

 
The evolution of pharmaceutical development

CSO, Dr Hank Agersborg, discusses drug development at CLINUVEL This audio file is available for download in mp3 format. Right click here and select “Save target as” to save this file to your computer.

 
Final year of filing MAA

CLINUVEL’s CSO, Dr Hank Agersborg, on the final year of drug filing CLINUVEL’s ASX announcement on the SU results can be found here. Read the CEO’s Technical note on the Phase II results here. This audio file is available for download in mp3 format. Right click here and select “Save target as” to save this file to your computer.

 
“Clinical and regulatory goals”

CLINUVEL’s senior management in regulatory affairs and clinical research discuss the development of CLINUVEL’s proprietary first-in-class drug, SCENESSE® (afamelanotide). Administered by physicians as a controlled-release resorbable implant, SCENESSE® is a preventative drug activating melanin – pigmentation – in the skin. Melanin provides a biological barrier, protecting skin from UV and visible light. Medically, this is […]

 
Light & UV In Australia

Australians have a love for their outdoors and a great appreciation for sunshine. With our appreciation comes understanding, and with that understanding, a healthy respect of the sun. In Australia, sun safety is paramount and education starts early. Year round, Australians are exposed to high levels of UV; two in three Australians are expected to […]